DIA Conference in India is Rescheduled
DIA has rescheduled its 3rd Annual Conference on Drug Discovery and Clinical Development in India, which was recently postponed due to recent violence in the area.
MUMBAI, INDIA—DECEMBER 18, 2008—
The Drug Information Association (DIA)
has rescheduled its
3rd Annual Conference on Drug Discovery and Clinical Development in India
(February 25-28, 2009; Mumbai, India).
“I would like to thank everyone for their patience and understanding for the inconvenience caused by the postponement,” says Sultan Ghani, DIA India Director. “I can assure you that DIA remains committed to its presence in India and is working with the host hotel to make sure that this meeting offers you the best educational and networking experience, under the safest and most secure conditions possible.”
Driven by the need to improve R&D productivity and efficiency and the desire to access untapped markets, global pharmaceutical companies have increasingly off shored and outsourced operations to India. A wide array of factors, however, can dictate whether such a move is successful. DIA will convene global experts from industry, academia, and regulatory for a provocative discussion on the challenges and issues facing drug discovery and clinical development in India. Topics will include:
• Development of Medical Devices: Global Regulatory Requirements
• Opportunities for Establishing Globally Centralized Laboratories in India
• India’s Patent Laws and their impact on Biopharmaceutical Industry
• India vs. ICH Regulatory Framework for Safety Reporting
• Bioinformatics and Biometrics
• Clinical Trials
• Combination Products
• Drug Delivery
• Drug Discovery
• Development of Anticancer Drugs and Biologics: PK
• Development of Biologics
• Pharmacology and Toxicology
• Pharmacovigilance
• Quality-by-Design
• Vaccine – The Challenge for Regulatory and Innovators
• Ethics in Clinical Research
About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit
or call 215-442-6100.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
